Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

Similar articles for PubMed (Select 21968148)

1.

Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population.

Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K.

Am J Nephrol. 2011;34(5):452-9. doi: 10.1159/000332378. Epub 2011 Oct 3.

PMID:
21968148
2.

APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.

Tzur S, Rosset S, Skorecki K, Wasser WG.

Nephrol Dial Transplant. 2012 Apr;27(4):1498-505. doi: 10.1093/ndt/gfr796. Epub 2012 Feb 22.

3.

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA.

J Am Soc Nephrol. 2011 Nov;22(11):2129-37. doi: 10.1681/ASN.2011040388. Epub 2011 Oct 13.

4.

Absence of HIV-associated nephropathy in Ethiopians.

Behar DM, Shlush LI, Maor C, Lorber M, Skorecki K.

Am J Kidney Dis. 2006 Jan;47(1):88-94.

PMID:
16377389
5.

APOL1 localization in normal kidney and nondiabetic kidney disease.

Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR.

J Am Soc Nephrol. 2011 Nov;22(11):2119-28. doi: 10.1681/ASN.2011010069. Epub 2011 Oct 13.

6.

Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K.

Hum Genet. 2010 Sep;128(3):345-50. doi: 10.1007/s00439-010-0861-0. Epub 2010 Jul 16.

7.

HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.

Atta MG, Estrella MM, Kuperman M, Foy MC, Fine DM, Racusen LC, Lucas GM, Nelson GW, Warner AC, Winkler CA, Kopp JB.

Kidney Int. 2012 Aug;82(3):338-43. doi: 10.1038/ki.2012.111. Epub 2012 Apr 11.

8.

APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.

Fine DM, Wasser WG, Estrella MM, Atta MG, Kuperman M, Shemer R, Rajasekaran A, Tzur S, Racusen LC, Skorecki K.

J Am Soc Nephrol. 2012 Feb;23(2):343-50. doi: 10.1681/ASN.2011060562. Epub 2011 Dec 1.

9.

APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.

Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D'Agati VD, Klotman PE, Gharavi AG.

J Am Soc Nephrol. 2011 Nov;22(11):1991-6. doi: 10.1681/ASN.2011040434. Epub 2011 Oct 13.

10.

Population genetics of chronic kidney disease: the evolving story of APOL1.

Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K.

J Nephrol. 2012 Sep-Oct;25(5):603-18. doi: 10.5301/jn.5000179. Review.

PMID:
22878977
11.

APOL1 and kidney disease.

Pollak MR, Genovese G, Friedman DJ.

Curr Opin Nephrol Hypertens. 2012 Mar;21(2):179-82. doi: 10.1097/MNH.0b013e32835012ab. Review.

PMID:
22257798
12.

Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators.

Kidney Int. 2013 Jan;83(1):114-20. doi: 10.1038/ki.2012.263. Epub 2012 Jul 25.

13.

APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle.

Hays T, Wyatt CM.

Kidney Int. 2012 Aug;82(3):259-60. doi: 10.1038/ki.2012.129.

PMID:
22791322
14.

Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J.

Kidney Int. 2012 Oct;82(7):805-11. doi: 10.1038/ki.2012.217. Epub 2012 Jun 13.

15.

High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria.

Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M, Rosset S, Skorecki K.

Nephron Clin Pract. 2013;123(1-2):123-8. doi: 10.1159/000353223. Epub 2013 Jul 13.

PMID:
23860441
16.

APOL1 variants associate with increased risk of CKD among African Americans.

Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH.

J Am Soc Nephrol. 2013 Sep;24(9):1484-91. doi: 10.1681/ASN.2013010113. Epub 2013 Jun 13.

17.

JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.

Divers J, Núñez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI.

Kidney Int. 2013 Dec;84(6):1207-13. doi: 10.1038/ki.2013.173. Epub 2013 May 15.

18.

End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End‐Stage Renal Disease Consortium.

Arthritis Rheumatol. 2014 Feb;66(2):390-6. doi: 10.1002/art.38220.

19.

Plasma apolipoprotein L1 levels do not correlate with CKD.

Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC.

J Am Soc Nephrol. 2014 Mar;25(3):634-44. doi: 10.1681/ASN.2013070700. Epub 2013 Nov 14.

20.

The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR.

J Am Soc Nephrol. 2010 Sep;21(9):1422-6. doi: 10.1681/ASN.2010070730. Epub 2010 Aug 5. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk